Insulet Appoints Mike Panos as Chief Commercial Officer to Drive Global Growth of Omnipod Platform
Insulet Corporation, a global leader in tubeless insulin pump technology, has announced the appointment of Mike Panos as Executive Vice President and Chief Commercial Officer. The appointment is effective immediately and reflects the company’s continued focus on scaling its commercial capabilities to support accelerating global demand for automated insulin delivery solutions.
In his new role, Panos will oversee Insulet’s global commercial organization, with responsibility for shaping and executing commercial strategy across markets worldwide. He will report directly to Ashley McEvoy, President and Chief Executive Officer, and will serve as a member of the company’s Executive Leadership Team.
Strengthening Commercial Leadership Amid Expanding Market Opportunity
The appointment comes at a time when Insulet is experiencing strong momentum driven by the growing adoption of automated insulin delivery systems in both type 1 and type 2 diabetes. With increasing recognition of the clinical benefits associated with these technologies, the company sees a significant opportunity to expand its global footprint and reach a broader patient population.
Ashley McEvoy emphasized that Insulet is actively strengthening its organizational capabilities to capture this growth opportunity. The company’s strategy centers on combining strong clinical outcomes with patient-focused innovation and expanding access to its flagship Omnipod platform.
By bringing in a seasoned commercial leader like Panos, Insulet aims to enhance its ability to execute on these priorities, scale its operations, and further solidify its position as a leader in diabetes management technology.
Extensive Leadership Experience in Medical Technology
Mike Panos joins Insulet with more than three decades of experience in the medical technology industry, having built a distinguished career at Stryker Corporation. Over the course of 30 years at Stryker, he held a range of senior leadership positions, contributing to the company’s growth across multiple business segments.
Most recently, Panos served as Leader of Sales Excellence, where he focused on optimizing commercial performance and driving best practices across the organization. Prior to that, he held prominent roles including President of the Trauma and Extremities Division and President of North America and Global Research and Development.
Throughout his career, Panos has demonstrated a strong track record of building and scaling high-performing sales organizations, expanding into new markets, and delivering sustained double-digit growth in competitive healthcare sectors. His expertise spans both strategic planning and operational execution, making him well positioned to lead Insulet’s global commercial efforts.
Proven Track Record in Driving Growth and Execution Excellence
Panos is widely recognized for his ability to develop top-tier commercial teams and instill disciplined execution across large, complex organizations. His leadership approach emphasizes talent development, accountability, and data-driven decision-making—key elements for success in today’s rapidly evolving healthcare landscape.
At Stryker, he played a critical role in driving market expansion and strengthening customer engagement, helping the company achieve consistent revenue growth. His experience managing global teams and navigating diverse healthcare markets will be particularly valuable as Insulet continues to expand internationally.
In addition to his professional accomplishments, Panos brings strong regional ties to Insulet’s Massachusetts-based headquarters. A graduate of Boston College and a long-time resident of the Boston area, he is well acquainted with the local business and healthcare ecosystem.
Leading Global Commercial Strategy at Insulet
In his new position, Panos will be responsible for overseeing all aspects of Insulet’s commercial operations worldwide. This includes driving sales performance, enhancing market access, and ensuring effective execution of the company’s growth strategy across different regions.
A key priority will be expanding access to the Omnipod platform, particularly in underserved markets and among patient populations that have not yet fully benefited from automated insulin delivery technology. This includes both geographic expansion and broader adoption among individuals with type 2 diabetes, an area of increasing focus for the company.
Panos will also play a central role in strengthening Insulet’s commercial infrastructure, ensuring that the organization is equipped to support continued growth. This includes optimizing sales processes, enhancing customer engagement, and leveraging data and analytics to improve decision-making.
Supporting the Transition to Automated Insulin Delivery as Standard of Care
The global diabetes landscape is undergoing a significant transformation, with automated insulin delivery systems increasingly becoming the standard of care. These technologies offer improved glycemic control, reduced risk of complications, and enhanced quality of life for patients.
Insulet’s Omnipod system stands out as a tubeless, wearable insulin pump that simplifies diabetes management and offers greater flexibility compared to traditional pump systems. Its user-friendly design and strong clinical outcomes have contributed to growing adoption among both patients and healthcare providers.
As Chief Commercial Officer, Panos will be instrumental in accelerating this adoption by ensuring that healthcare professionals, payers, and patients are fully aware of the benefits of the Omnipod platform. His efforts will also focus on expanding reimbursement coverage and improving access to the technology in key markets.
Leadership Perspective and Vision
Commenting on his appointment, Panos expressed enthusiasm about joining Insulet at a pivotal moment in its growth journey. He highlighted the company’s strong foundation, driven by innovative technology, compelling clinical data, and a well-established brand in the diabetes care market.
He also emphasized the significant opportunity to expand the reach of automated insulin delivery systems, particularly among patients who have not yet had access to these advanced solutions. By strengthening commercial execution and fostering collaboration across teams, Panos aims to help Insulet unlock the full potential of its platform.
His vision aligns closely with the company’s broader mission to improve the lives of people with diabetes by providing simple, effective, and accessible treatment options.
Positioning for Long-Term Growth
The addition of Panos to Insulet’s leadership team underscores the company’s commitment to investing in talent and capabilities that can support long-term growth. As the demand for advanced diabetes management solutions continues to rise, having a strong commercial organization will be critical to maintaining competitive advantage.
Insulet’s focus on innovation, combined with its expanding global presence, positions it well to capitalize on emerging opportunities in the healthcare market. With Panos leading the commercial function, the company is expected to further enhance its ability to scale operations and deliver value to patients, providers, and stakeholders.
The appointment of Mike Panos as Chief Commercial Officer marks an important step in Insulet’s ongoing evolution as a leader in diabetes technology. With extensive experience in the medical device industry and a proven ability to drive commercial success, Panos brings valuable expertise to the organization.
As Insulet continues to expand the reach of its Omnipod platform and advance the adoption of automated insulin delivery, strong commercial leadership will play a crucial role in achieving its strategic goals. Through this appointment, the company is reinforcing its commitment to growth, innovation, and improving outcomes for people living with diabetes worldwide.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle.
Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the US or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.
Source Link:https://www.businesswire.com/
